Daily pills and frequent clinic visits are a major barrier to infectious diseases prevention and treatment, especially in low- and middle-income countries. Long-acting technologies can reduce pill burden, frequency of clinic visits and the costs of repeated travel to health facilities.
Daily pills and frequent clinic visits are a major barrier to infectious diseases prevention and treatment, especially in low- and middle-income countries (LMICs). Long-acting technologies (LATs), including injectables, implants, pills, and microneedle patches also known as microarray patches (MAPs), can…
The WHO Global TB Program's Accelerator Platform for Novel TB Regimens held its 12th meeting to examine the four-month HPMZ (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen for tuberculosis treatment, covering country experiences, implementation tools, and next steps for rollout. Despite the World Health Organization's (WHO) 2022 recommendation, implementation has remained limited, with challenges such as high pill burden and medicine costs cited as potential barriers.
TAG and KNCV are excited to present an upcoming webinar: Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care on Tuesday, June 20, at 9 a.m. EST. This is the latest installment in the series of virtual trainings for community and civil society organizations hosted by TAG under the Unitaid-funded ASCENT DR-TB Project.
Join TAG on April 16 at 8:30 a.m. ET for a practical webinar on drug safety monitoring in TB treatment. Learn how to identify side effects, support patient safety, and understand pharmacovigilance in the context of newer, all-oral DR-TB regimens.
The 2026 Pre-CROI Community HIV Cure Research Workshop took place on Saturday, February 21, in Denver. Check out all of the recordings and slides, now linked.
New tuberculosis (TB) vaccines could be realized as soon as 2028 — radically reshaping the journey to eliminate TB. Communities and civil society organizations are poised to play a vital role in the introduction of a future TB vaccine as central protagonists of this next chapter for TB elimination.
In this interactive November 2025 webinar, TAG and our partners highlighted some of the federal policies, executive orders, and funding cuts that have been impacting TB research since the beginning of 2025.
TAG is organizing this webinar on July 29 for community organizations and advocates to raise awareness about the HCV Elimination bill, and prepare them to meet and engage with their Senators during the August recess in their district offices or Town Hall meetings.
TAG was among thirteen organizations that cosponsored this Congressional briefing held on July 9, 2025. Briefing materials and presentations are available for download.